$GLPG LongI am long NASDAQ:GLPG on the channel breaks. I have about 1.5% of my account into this play but I will add as price continues lower.
GLPG trade ideas
Galapagos to break below 7 year low?Galapagos - Intraday - We look to Sell a break of 40.98 (stop at 43.03)
Daily signals are bearish.
There is no clear indication that the downward move is coming to an end.
Trades at the lowest level in 38 weeks.
The previous low is located at 41.30.
A break of 41.00 is needed to confirm follow through negative momentum.
Our profit targets will be 36.33 and 34.33
Resistance: 45.00 / 47.00 / 49.00
Support: 43.00 / 41.00 / 39.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses
Galapagos (GLPG.as) bearish scenario:The technical figure Triangle can be found in the Belgium company Galapagos NV (GLPG.as) at daily chart. Galapagos NV (formerly known as Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis. The Triangle has broken through the support line on 26/07/2022, if the price holds below this level you can have a possible bearish price movement with a forecast for the next 7 days towards 45.00 EUR. Your stop loss order according to experts should be placed at 56.70 EUR if you decide to enter this position.
Galapagos agreed to acquire CellPoint and AboundBio in an all-cash transaction propelling into next-generation cell therapy while significantly broadening its portfolio and capabilities.
Galapagos will pay an upfront amount of €125 million for CellPoint, an additional €100 million to be paid upon achieving certain milestones, and $14 million for AboundBio.
Galapagos said that, through the acquisition of CellPoint and AboundBio, it gains access to an automated point-of-care cell therapy supply model and a next-generation fully human antibody-based therapeutics platform.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
GLPGAt the moment there is a strong support on the daily 200 MA that happens to correlate with the weekly 50 MA. I think this support will hold and that the price will move to the 0.5 fib which happens to lay just beneeth the weekly 200 MA.
Nothing I say is financial advice.
GLPG.BR completing 3rd wave up off the Dec lowTLDR: targeting 80 if next pull back holds 56.
--
Galapagos has gained more than 50% nominally off the Dec '21 low, in a three waves structure.
While running into the 1.618 extension of the green circle i-ii, the technicals are becoming overbought.
With the next earning report within a month, it seems wise to take some profits off the tabel.
Further more, the 65 region also happens to be near:
- an important volume wedge on the weekly ~68 EUR;
- the orange 2.0-2.618 extension, a typical target range for the impulsive subwave v of circle iii;
- the 0.236 retracement of the higher degree correction started in Feb 2020, before the covid crash;
Therefor resistance is expected, a pull back could be starting soon.
Assuming we are topping somewhere between the green 1.618-1.764 extension, ideally the pull back holds above 57-58 region as circle iv to jump start circle v targeting 80 region.
A drop under 56 will be the first warning that this rally is topped in three waves, while dropping under 52 will have me reconsider whether there is any bullish potential left in the near term.
Bigger picture (monthly chart: )
Off the ATH struct in Feb '20, GLPG has corrected more than 80% nominally, but when putting it in logarithmic perspective, it was merely a 0.382 retracement after a phenomenal run from 2.74 to 250.9, almost 100x in 12 years. The long term trend line has never been violated, and the monthly technicals are trying to turn upward again.
Now that we are back to a make-or-break level like the dips in 2011 and 2014, the stop limit to the down side is clearly defined while the potential upside is still beyond imagination.
A hard stop should be placed just under 44, as given the tiny volume in between, the next long term support will likely not be found until 0.618 retracement ~15 EUR.
Conclusion: with 0.382 retracement from ATH ~45 EUR as long term support, maintaining immediate bullish bias as long as next pull back holds above 56.
Careful LONG GLPGI've been following this tock for quit some time. Seeing it fall and many people calling to go LONG, only to fall even further. The cash position alone equals 80 share price. Fundamental Mumbo Jumbo. The chart had much more downside to go.
Now we have a potential bottom forming. The RSI is oversold on the Weekly & monthly levels & looks to tackle the Averages. Altough it did break an important level, this might be 'overextending' and will return soon.
This is still too early to call BULL. But I'm liking the setup so far. This is BIOTECH so very volatile. I don't see the company going bankrupt. I like to buy low so when the RSI on weekly & monthly are this low it sparks my intrest.
The stock can still go lower perhaps to 33 the previous lows.
I think the key indicators will be:
* Breaking above resitence
* breaking above the 200 dMA AND staying above it.
* GLPG must trade and stay above 60
* Moving averages must point to a bull market: 21 - 50 - 100 - 200 (whilest today it is in reverse = bear market)
T1: 82
T2: 98
T3: 150
The choice is yours.. :)
GLPG high R:R speculative play not for the faint-heartedConclusion
If current retracement levels hold and subsequently break above 74, bull case targeting 400+ is in play.
First indication of upside would be recovering 60.
Technical
Nominally dropped over 80% sinds the wave 3 top in 2020, while volume profile suggests uphill battle toward 60 is tough.
But putting it in a logarithmic perspective, the wave 4 retrace seems more reasonable, currently right between 0.618 and 0.5 long term fibs (pink).
The daily RSI is making higher highs and higher lows, looking for confirmation in the weekly.
Immediate bull case considered broken under circle b of 3, while taking out volume profile POC and top circle a of 3 favors bullish interpretation.
Fundamental
They have more cash on balance then market cap, which means investors value their ongoing programs below zero.
Surely research costs money so the cash holding is a moving target, but there is no need to dilute current shareholders for the next few years.
Emotional
Founder-CEO got blamed for not yielding results in the US, although IMHO entrepreneur who takes risks (w/o costing the society a lot) should be praised instead.
His decision to step down causing a pop in the share price is not what he deserves.
Not to mention that Filgotinib did get approval from the EU, which should help to slow down the cash burn a little.
Hopium is the ongoing programs produce better result, and/or Filgo eventually gets approved in the states.
Disclosure
Already long shares at 50, albeit a tiny qty for observation purpose only, stop under 35.
Will long calls if breakout confirm.
Galapagos is it time to buy ? DYOR NFAHealthcare has been getting slapped as of late but there are some fine investment opportunities. Galapagos is one I have been keeping an eye on. It has formed a broadening wedge on the long term and holding nicely on the support line. Fisher on the monthly frame has crossed up and MACD is showing signs of levelling off. LTF, day especially is showing signs of a nice bottom.
price channels galapagosmaybe we find support at 45. I think we wont see it lower.. galapagos is still a good company with lots of cash.
Galapagos breaking out various falling wedge patterns today!Galapagos springt uit zijn meer dan een jaar oude dalende wig. Volume vandaag geeft aan dat kopers de overhand gaan krijgen. Bevestiging zou moeten komen van nog een stevige candlestick en mogelijk openingskoers met een gap tot boven de MA50!
Galapagos broke out of its one year(+) old falling wegde.. I believe a first sign of a powerfull recovery. Some ting to keep an eye on, look at the buying volume of today. Confirmation should follow by with another solid green candle and possibly above the MA50.
GLPG AnalysisWeekly Chart. Looks for a reversal in the up trend. Let's see if it will test its first resistance and break out.
Falling wedge on dailyIt looks like GLPG has hit the bottom and will try to break the resistance (of the falling wedge) to the upside
GLPG LARGOI am optimistic with GLPG, the share has been hit by its alliance with gilead but in the technical aspect it is at a bargain price taking into account that in the monthly graph it has not yet lost the upward trend, until it goes below 60 the trend remains on the upside, several of my indicators give me micro-trend change at this point, plus we have a beautiful harmonic butterfly pattern. My ticket will be at current price today 73.38 with SL at 57-56.
THIS IS NOT AN INVESTMENT ADVICE DO YOUR OWN INVESTIGATION
Galapagos - Strong buy PT $240 > $480We think Galapagos is undervalued at current levels. The price will be heading $240 soon.
Cup and Handle formation.
The RSI / MACD and volume showing signs of recovery from recent 60% correction.
First price target: $ 240
Second price target: $350 - $480 (2022/23)
Full year 2020 results:
18 Febuary 2021
Webcast 19 February 2021, 14.00 CET
Events:
January 27, 2021
Degroof Petercam Healthcare Conference
February 23, 2021
10th Annual SVB Leerink Global Healthcare Conference 2021
March 01, 2021
Raymond James virtual Institutional Investors Conference
March 01, 2021
Cowen 41st Annual Health Care Conference
March 02, 2021
Credit Suisse London 2021 Healthcare Conference
March 09, 2021
Barclays Global Healthcare Conference
May 05, 2021
Kempen’s Life Sciences Conference
May 11, 2021
BofA Global Research 2021 Health care conference
June 15, 2021
Citi 10th Annual European Healthcare Conference
September 08, 2021
Citi Global Biopharma Conference
September 22, 2021
Bernstein’s 18th Annual Strategic Decisions Conference (SDC)
November 16, 2021
Stifel 2021 Healthcare Conference
GLPG analyseLet's see what the price does. Casually optimistic that the price is at it's low here at 80 EUR.
I would buy at the downward or horizontal line for a trade. There are better looking charts and manage your risk under de 50d SMA!
Ready for BulishFDA provides preliminary approval for the drug filgotinib not approved, Galapagos will now assume full responsibility for filgotinib in Europe. Gilead will pay EUR 160 million to Galapagos to accelerate commercial activities in Europe. The gap from 19 march 2019 is filled....ready for the turn up..... what do you think?
GLPG ; Trend reversalGalapagos is at a 52-week low.
A bottom has been set, now it is time for a trend reversal.
